用于治疗炎症性肠道疾病的药物成本
Rasmus Rankala1, Anssi Mustonen1, Markku Voutilainen1
1Department of Internal Medicine, Turku University Hospital, University of Turku, Turku, Finland.
Scandinavian journal of gastroenterology
|August 29, 2023
概括
芬兰的炎症性肠病 (IBD) 药物费用很高,平均每年每患者1428欧元. 克罗恩氏病患者的费用更高,特别是生物药品的费用更高,影响了治疗负担能力.
科学领域:
- 胃肠病学 胃肠病学
- 卫生经济学 卫生经济学
- 药物经济学 药物经济学
背景情况:
- 炎症性肠病 (IBD),包括克罗恩病 (CD) 和性结肠炎 (UC),对终身健康和经济负担具有重大影响.
- 近年来,IBD的发病率和流行率在全球范围内都在上升.
- 关于芬兰IBD患者产生的特定药物成本的数据有限.
研究的目的:
- 综合评估芬兰炎症性肠病 (IBD) 患者的实际药物成本.
- 为了确定克罗恩病 (CD) 和性结肠炎 (UC) 患者之间的成本差异.
- 探索临床标志物,皮质类固醇使用和药物支出之间的相关性.
主要方法:
- 一种混合方法的方法,结合了问卷,医院记录和国家注册.
- 包括561名被诊断患有IBD (克罗恩病或性结肠炎) 的患者.
- 详细分析药物采购成本,包括针对特定药物类别的子组分析.
主要成果:
- 每位IBD患者的平均年度药物成本为1428欧元.
- 与性结肠炎患者 (902欧元) 相比,克罗恩氏病患者的年药费 (2369欧元) 显著增加.
- 在免疫抑制剂,皮质类固醇和生物亚组中观察到CD患者的成本较高;皮质类固醇使用与特定的临床标记相关;妇女报告说,尽管生活质量较差,但成本较低.
结论:
- 药品是IBD治疗成本的主要驱动因素.
- 越来越多地使用生物疗法是导致IBD管理中药物支出增加的一个关键因素.
更多相关视频
相关概念视频
Inflammatory Bowel Disease IV: Pharmacological Management
152
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
152
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
195
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
195
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
149
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
149
Drugs for Treatment of Ulcerative Colitis in IBD
173
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
173
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
173
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
173
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
354
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
354


